Cingal TM , Monovisc ® and Orthovisc ® may not be suitable for everyone. Talk to your doctor if you have questions regarding these products, or for more information on pain associated with osteoarthritis of the knee. Product information is only pertinent for use in Canada. Cingal TM , Monovisc ® and Orthovisc ® are trademarks of Anika Therapeutics Inc., used under licence by Pharmascience Inc. Pendopharm, Division of Pharmascience Inc. Product Licences are pertinent to use in Canada. Product Licences herein are not approved for use in the .
For example, people undergoing dialysis face multiple challenges. First, they must cope with the loss of function of their kidneys. This is a devastating loss, which is often accompanied by a great deal of anxiety, depression, and grieving. Second, dialysis means adopting an entirely new lifestyle – one in which several days a week are devoted to treatment. Third, a majority of people in dialysis feel exhausted after the procedure, and cannot do anything strenuous the rest of the day. Fourth, they must accept strict dietary restrictions to maintain their health.
Patients requiring oral corticosteroids should be weaned slowly from systemic corticosteroid use after transferring to Advair Diskus. Prednisone reduction can be accomplished by reducing the daily prednisone dose by mg on a weekly basis during therapy with Advair Diskus. Lung function (mean forced expiratory volume in 1 second [FEV 1 ] or morning peak expiratory flow [AM PEF]), beta-agonist use, and asthma symptoms should be carefully monitored during withdrawal of oral corticosteroids. In addition, patients should be observed for signs and symptoms of adrenal insufficiency, such as fatigue, lassitude, weakness, nausea and vomiting, and hypotension.